BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

5:51 PM
 | 
Sep 29, 2008
 |  BC Extra  |  Company News

NICE issues Tarceva guidance

The U.K's NICE issued a final appraisal determination (FAD) for Tarceva erlotinib from Roche (SWX:ROG) to treat non-small cell lung cancer (NSCLC). The agency recommended the drug as an alternative to docetaxel as a second-line treatment for NSCLC only when...

Read the full 187 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >